# US 2026/0285961 A1 · Anti-vegfa antibody or antigen-binding fragment thereof and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0285961 A1
- Document ID: US20260285961A1
- Status: Published application
- Kind: A1
- Application number: 19/111,673
- Filed: 2023-09-13
- Published: 2026-09-24
- Earliest claimed: 2022-09-14
- Assignees: Quaerite Biopharm Research (Beijing) Co., Ltd.
- Applicants: Quaerite Biopharm Research (Beijing) Co., Ltd.
- Inventors: Jinliang HUANG; Huiqin LIU
- Web page: https://patentgrep.com/patent/US20260285961A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- G01N 2333/475: Assays involving growth factors
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are an anti-VEGFA antibody or an antigen-binding fragment thereof and use thereof. The anti-VEGFA antibody or the antigen-binding fragment thereof features high thermal stability, high water solubility, small molecular weight, simple expression and purification processes, and high affinity for VEGFA, and is capable of effectively blocking the VEGFA signaling pathway and effectively blocking VEGFA-induced pathological processes such as vascular endothelial cell proliferation and angiogenesis, thus having potential applications in the treatment of VEGFA-associated diseases.

## Claims

### Claim at position 1

1-24. (canceled)

### Claim 25

An anti-VEGFA antibody or an antigen-binding fragment thereof, comprising CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable region, wherein
an amino acid sequence of the CDR-H1 comprises SYTMG (SEQ ID NO: 1) or an amino acid sequence having at least 80% identity to SYTMG (SEQ ID NO: 1);
an amino acid sequence of the CDR-H2 comprises AISKGGYKYX1X2VSLEA (SEQ ID NO: 2) or an amino acid sequence having at least 80% identity to AISKGGYKYX1X2VSLEA (SEQ ID NO: 2);
an amino acid sequence of the CDR-H3 comprises TRAYGSSRLX3LAX4TYEY (SEQ ID NO: 3) or an amino acid sequence having at least 80% identity to TRAYGSSRLX3LAX4TYEY (SEQ ID NO: 3).

### Claim 26 (depends on 25)

The anti-VEGFA antibody or the antigen-binding fragment thereof according to claim 25, wherein X1X2 in SEQ ID NO: 2 represents DS, DA, NT, DT, NA, or NS; X3 in SEQ ID NO: 3 represents R or K, and X4 in SEQ ID NO: 3 represents D, N, E, or K.

### Claim 27 (depends on 26)

The anti-VEGFA antibody or the antigen-binding fragment thereof according to claim 26, wherein the amino acid sequences of the CDR-H1, the CDR-H2, and the CDR-H3 comprise any one of the following groups:
A) SEQ ID NOs: 1, 4, and 9;
B) SEQ ID NOs: 1, 5, and 9;
C) SEQ ID NOs: 1, 6, and 10;
D) SEQ ID NOs: 1, 4, and 11;
E) SEQ ID NOs: 1, 7, and 12;
F) SEQ ID NOs: 1, 6, and 11;
G) SEQ ID NOs: 1, 4, and 10;
H) SEQ ID NOs: 1, 5, and 12;
I) SEQ ID NOs: 1, 4, and 12;
J) SEQ ID NOs: 1, 8, and 12; and
K) SEQ ID NOs: 1, 33, and 34.

### Claim 28 (depends on 25)

The anti-VEGFA antibody or the antigen-binding fragment thereof according to claim 25, comprising a humanized sequence, wherein an engineered site of the humanized sequence is located in a non-CDR region.

### Claim 29 (depends on 25)

The anti-VEGFA antibody or the antigen-binding fragment thereof according to claim 25, wherein the anti-VEGFA antibody or the antigen-binding fragment thereof is a nanobody, a chimeric antibody, a Fab fragment, a Fab′ fragment, a Fd fragment, a Fd′ fragment, a Fv fragment, a dAb fragment, an isolated CDR, a F(ab′)2 fragment, a single domain antibody, a single chain antibody molecule, or a linear antibody.

### Claim 30 (depends on 25)

The anti-VEGFA antibody or the antigen-binding fragment thereof according to claim 25, wherein an amino acid sequence of the anti-VEGFA antibody or the antigen-binding fragment thereof comprises any one of the amino acid sequences of SEQ ID NOs: 13-32, 35-61, and 64-67, or has at least 80% identity to any one of the amino acid sequences of SEQ ID NOs: 13-32, 35-61, and 64-67.

### Claim 31 (depends on 25)

The anti-VEGFA antibody or the antigen-binding fragment thereof according to claim 25, wherein the anti-VEGFA antibody or the antigen-binding fragment thereof binds to a human or monkey VEGFA protein.

### Claim 32 (depends on 25)

A fusion protein, comprising the anti-VEGFA antibody or the antigen-binding fragment thereof according to claim 25.

### Claim 33 (depends on 32)

The fusion protein according to claim 32, further comprising, in addition to the anti-VEGFA antibody or the antigen-binding fragment thereof, an additional anti-VEGFA antibody or an antigen-binding fragment thereof, or an antibody against an additional target or an antigen-binding fragment thereof, or an additional functional component.

### Claim 34 (depends on 25)

A product, wherein the product comprising any one of the following groups:
1) a chimeric antigen receptor, wherein an extracellular domain of the chimeric antigen receptor comprises the anti-VEGFA antibody or the antigen-binding fragment thereof according to claim 25;
2) an immune cell expressing the anti-VEGFA antibody or the antigen-binding fragment thereof or the chimeric antigen receptor according to 1) above;
3) a nucleic acid encoding the anti-VEGFA antibody or the antigen-binding fragment thereof or encoding the fusion protein comprising the anti-VEGFA antibody or the antigen-binding fragment thereof;
4) a vector, comprising the nucleic acid according to 3) above;
5) a host cell, comprising the nucleic acid according 3) above or the vector according to 4) above.

### Claim 35 (depends on 25)

A method for detecting VEGFA, comprising contacting a sample to be tested with the anti-VEGFA antibody or the antigen-binding fragment thereof according to claim 25, and subsequently detecting the content of a complex formed by VEGFA and the anti-VEGFA antibody or the antigen-binding fragment thereof.

### Claim 36 (depends on 25)

A method for treating and/or preventing a disease, comprising administering to an individual the anti-VEGFA antibody or the antigen-binding fragment thereof according to claim 25, or a fusion protein comprising the anti-VEGFA antibody or the antigen-binding fragment thereof, or contacting the anti-VEGFA antibody or the antigen-binding fragment thereof, or a fusion protein comprising the anti-VEGFA antibody or the antigen-binding fragment thereof with a target cell.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the target cell is selected from cells expressing VEGFA, such as cardiomyocytes, renal proximal tubule cells, hepatocytes, vascular endothelial cells, granulosa cells, specialized epithelial cells, mesenchymal cells, macrophages, platelets, dendritic cells, activated T cells, retinal pigment epithelial cells, Muller cells in the retina, astrocytes, osteoblasts, bronchial and alveolar epithelial cells, pericytes, vascular smooth muscle cells, myofibroblasts, keratinocytes, renal mesangial cells, tumor cells, etc.

### Claim 38 (depends on 36)

The method according to claim 36, wherein the disease is a disease associated with the VEGFA signaling pathway.

### Claim 39 (depends on 25)

A method for blocking VEGFA-mediated vascular endothelial cell proliferation or inhibiting angiogenesis, comprising contacting a vascular endothelial cell with the anti-VEGFA antibody or the antigen-binding fragment thereof according to claim 25, or a fusion protein comprising the anti-VEGFA antibody or the antigen-binding fragment thereof.
